Anti-PLMN/ PLG monoclonal antibody

Anti-PLMN/ PLG antibody for FACS & in-vivo assay

Target products collectionGo to PLG/PLG products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T89034-Ab-1/ GM-Tg-hg-T89034-Ab-2Anti-Human PLG monoclonal antibodyHuman
GM-Tg-rg-T89034-Ab-1/ GM-Tg-rg-T89034-Ab-2Anti-Rat PLG monoclonal antibodyRat
GM-Tg-mg-T89034-Ab-1/ GM-Tg-mg-T89034-Ab-2Anti-Mouse PLG monoclonal antibodyMouse
GM-Tg-cynog-T89034-Ab-1/ GM-Tg-cynog-T89034-Ab-2Anti-Cynomolgus/ Rhesus macaque PLG monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T89034-Ab-1/ GM-Tg-felg-T89034-Ab-2Anti-Feline PLG monoclonal antibodyFeline
GM-Tg-cang-T89034-Ab-1/ GM-Tg-cang-T89034-Ab-2Anti-Canine PLG monoclonal antibodyCanine
GM-Tg-bovg-T89034-Ab-1/ GM-Tg-bovg-T89034-Ab-2Anti-Bovine PLG monoclonal antibodyBovine
GM-Tg-equg-T89034-Ab-1/ GM-Tg-equg-T89034-Ab-2Anti-Equine PLG monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T89034-Ab-1/ GM-Tg-hg-T89034-Ab-2; GM-Tg-rg-T89034-Ab-1/ GM-Tg-rg-T89034-Ab-2;
GM-Tg-mg-T89034-Ab-1/ GM-Tg-mg-T89034-Ab-2; GM-Tg-cynog-T89034-Ab-1/ GM-Tg-cynog-T89034-Ab-2;
GM-Tg-felg-T89034-Ab-1/ GM-Tg-felg-T89034-Ab-2; GM-Tg-cang-T89034-Ab-1/ GM-Tg-cang-T89034-Ab-2;
GM-Tg-bovg-T89034-Ab-1/ GM-Tg-bovg-T89034-Ab-2; GM-Tg-equg-T89034-Ab-1/ GM-Tg-equg-T89034-Ab-2
Products NameAnti-PLG monoclonal antibody
Formatmab
Target NamePLG
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PLG benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PLMN/ PLG VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLPm004371mouse Plg Lentivirus plasmid
    ORF Viral VectorvGMLPm004371mouse Plg Lentivirus particle


    Target information

    Target IDGM-T89034
    Target NamePLG
    Gene ID5340,18815,85253,703891,403602,101095261,280897,100050531
    Gene Symbol and SynonymsAb1-346,HAE4,LPA,Pg,PLG
    Uniprot AccessionP00747,Q01177,P12545,P80009,P06868,P80010
    Uniprot Entry NamePLMN_HUMAN,PLMN_MACMU,PLMN_RAT,PLMN_CANLF,PLMN_BOVIN,PLMN_HORSE
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseAcute appendicitis, Nephrotic syndrome
    Gene EnsemblENSG00000122194
    Target ClassificationN/A

    The target: PLG, gene name: PLG, also named as . The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflamation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.